Published
{
"ticker": "ISRG",
"cik": "0001035267",
"company": "Intuitive Surgical, Inc.",
"business_type": "industrial",
"schema_template": "standard industrial (medical technology): product and service revenue and cost of revenue, gross profit, SG&A, R&D, a separately presented antitrust litigation settlement, income from operations, interest and other income, income taxes, net income with the noncontrolling-interest split, basic and diluted EPS and weighted shares; the full balance sheet including cash and investments; operating, investing and financing cash flow with capital expenditures and free cash flow; share repurchases; revenue by type (instruments and accessories, systems, services) and by geography (U.S. and outside the U.S.); and the company's own non-GAAP measures from its third-quarter 2026 earnings release",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual US dollars (not millions); per-share amounts in dollars; share counts in actual shares",
"units_notes_seen": {
"FY2025 10-K consolidated balance sheets": "(IN MILLIONS, EXCEPT PAR VALUE AMOUNTS)",
"FY2025 10-K consolidated statements of income": "(IN MILLIONS, EXCEPT PER SHARE AMOUNTS)",
"FY2025 10-K consolidated statements of stockholders' equity": "(IN MILLIONS) (share counts in the Shares column are also in millions)",
"FY2025 10-K consolidated statements of cash flows": "(IN MILLIONS)",
"FY2025 10-K Note 5 revenue by geography and type": "(in millions)",
"Q3 2026 10-Q condensed consolidated balance sheets": "in millions (except par values)",
"Q3 2026 10-Q condensed consolidated statements of comprehensive income": "in millions (except per share amounts)",
"Q3 2026 10-Q condensed consolidated statements of cash flows": "in millions",
"Q3 2026 10-Q Note 5 revenue by geography and type": "(in millions)",
"Q3 2026 10-Q Note 9 stockholders' equity tables": "(in millions)",
"Q3 2026 10-Q Note 9 stock repurchase table": "(in millions, except per share amounts)",
"Q3 2026 earnings release (Exhibit 99.1) GAAP to non-GAAP reconciliation": "(IN MILLIONS, EXCEPT PER SHARE DATA)"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "none; Intuitive Surgical reports in US dollars",
"split_note": "Intuitive Surgical's 3-for-1 stock split took effect in October 2021, before every period shown here, so all per-share figures and share counts are already on a post-split basis and none have been adjusted."
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2025-01-01",
"period_end": "2025-12-31",
"period_type": "fiscal year",
"source_accession": "0001035267-26-000010",
"income_statement": {
"product_revenue": 8492600000,
"service_revenue": 1572100000,
"total_revenue": 10064700000,
"product_cost_of_revenue": 2866100000,
"service_cost_of_revenue": 556300000,
"total_cost_of_revenue": 3422400000,
"gross_profit": 6642300000,
"selling_general_and_administrative": 2385000000,
"research_and_development": 1311800000,
"total_operating_expenses": 3696800000,
"income_from_operations": 2945500000,
"interest_and_other_income_net": 365900000,
"income_before_taxes": 3311400000,
"income_tax_expense": 434800000,
"net_income": 2876600000,
"net_income_attributable_to_noncontrolling_interest": 20600000,
"net_income_attributable_to_intuitive_surgical": 2856000000,
"basic_eps": 8,
"diluted_eps": 7.87,
"basic_shares": 356900000,
"diluted_shares": 362700000
},
"balance_sheet": {
"cash_and_cash_equivalents": 3368000000,
"short_term_investments": 2566900000,
"accounts_receivable_net": 1527300000,
"inventory": 1840000000,
"prepaids_and_other_current_assets": 477300000,
"total_current_assets": 9779500000,
"property_plant_and_equipment_net": 5342400000,
"long_term_investments": 3099200000,
"deferred_tax_assets": 1018600000,
"intangible_and_other_assets_net": 848700000,
"goodwill": 370300000,
"total_assets": 20458700000,
"accounts_payable": 255100000,
"accrued_compensation_and_employee_benefits": 648400000,
"deferred_revenue": 506700000,
"other_accrued_liabilities": 596000000,
"total_current_liabilities": 2006200000,
"other_long_term_liabilities": 510800000,
"total_liabilities": 2517000000,
"additional_paid_in_capital": 10768500000,
"retained_earnings": 7011800000,
"accumulated_other_comprehensive_income_loss": 43300000,
"total_intuitive_surgical_stockholders_equity": 17824000000,
"noncontrolling_interest_in_joint_venture": 117700000,
"total_stockholders_equity": 17941700000,
"common_shares_outstanding": 355100000,
"cash_cash_equivalents_and_investments": 9034100000
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 614700000,
"amortization_of_intangible_and_other_assets": 62400000,
"deferred_income_taxes": 19100000,
"share_based_compensation": 788200000,
"operating_cash_flow": 3030500000,
"purchases_of_investments": -1215900000,
"proceeds_from_sales_of_investments": 259900000,
"proceeds_from_maturities_of_investments": 2175500000,
"capital_expenditures": -539800000,
"acquisitions_net_of_cash_intellectual_property_and_other_investing": -13900000,
"net_cash_from_investing_activities": 665800000,
"proceeds_from_employee_stock_plans": 350300000,
"taxes_paid_for_net_share_settlement_of_equity_awards": -419100000,
"repurchases_of_common_stock": -2295300000,
"net_cash_from_financing_activities": -2364100000,
"effect_of_exchange_rate_changes": 12800000,
"net_change_in_cash_cash_equivalents_and_restricted_cash": 1345000000,
"cash_cash_equivalents_and_restricted_cash_end_of_period": 3407400000,
"free_cash_flow": 2490700000
},
"revenue_by_type": {
"instruments_and_accessories": 6018900000,
"systems": 2473700000,
"services": 1572100000,
"total_revenue": 10064700000
},
"revenue_by_geography": {
"united_states": 6815800000,
"outside_united_states": 3248900000
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2024-01-01",
"period_end": "2024-12-31",
"period_type": "fiscal year",
"source_accession": "0001035267-26-000010",
"income_statement": {
"product_revenue": 7045000000,
"service_revenue": 1307100000,
"total_revenue": 8352100000,
"product_cost_of_revenue": 2313100000,
"service_cost_of_revenue": 404800000,
"total_cost_of_revenue": 2717900000,
"gross_profit": 5634200000,
"selling_general_and_administrative": 2140000000,
"research_and_development": 1145300000,
"total_operating_expenses": 3285300000,
"income_from_operations": 2348900000,
"interest_and_other_income_net": 324900000,
"income_before_taxes": 2673800000,
"income_tax_expense": 336300000,
"net_income": 2337500000,
"net_income_attributable_to_noncontrolling_interest": 14900000,
"net_income_attributable_to_intuitive_surgical": 2322600000,
"basic_eps": 6.54,
"diluted_eps": 6.42,
"basic_shares": 355200000,
"diluted_shares": 362000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 2027400000,
"short_term_investments": 1985900000,
"accounts_receivable_net": 1225400000,
"inventory": 1487200000,
"prepaids_and_other_current_assets": 385100000,
"total_current_assets": 7111000000,
"property_plant_and_equipment_net": 4646600000,
"long_term_investments": 4819100000,
"deferred_tax_assets": 1045100000,
"intangible_and_other_assets_net": 773900000,
"goodwill": 347500000,
"total_assets": 18743200000,
"accounts_payable": 193400000,
"accrued_compensation_and_employee_benefits": 535600000,
"deferred_revenue": 468800000,
"other_accrued_liabilities": 547500000,
"total_current_liabilities": 1745300000,
"other_long_term_liabilities": 468300000,
"total_liabilities": 2213600000,
"additional_paid_in_capital": 9681300000,
"retained_earnings": 6803300000,
"accumulated_other_comprehensive_income_loss": -51300000,
"total_intuitive_surgical_stockholders_equity": 16433700000,
"noncontrolling_interest_in_joint_venture": 95900000,
"total_stockholders_equity": 16529600000,
"common_shares_outstanding": 356600000,
"cash_cash_equivalents_and_investments": 8832400000
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 445300000,
"amortization_of_intangible_and_other_assets": 54400000,
"deferred_income_taxes": -135300000,
"share_based_compensation": 676800000,
"operating_cash_flow": 2415000000,
"purchases_of_investments": -5139600000,
"proceeds_from_sales_of_investments": 100200000,
"proceeds_from_maturities_of_investments": 2878800000,
"capital_expenditures": -1111200000,
"acquisitions_net_of_cash_intellectual_property_and_other_investing": -1000000,
"net_cash_from_investing_activities": -3272800000,
"proceeds_from_employee_stock_plans": 429400000,
"taxes_paid_for_net_share_settlement_of_equity_awards": -270000000,
"repurchases_of_common_stock": 0,
"net_cash_from_financing_activities": 150900000,
"effect_of_exchange_rate_changes": -800000,
"net_change_in_cash_cash_equivalents_and_restricted_cash": -707700000,
"cash_cash_equivalents_and_restricted_cash_end_of_period": 2062400000,
"free_cash_flow": 1303800000
},
"revenue_by_type": {
"instruments_and_accessories": 5079000000,
"systems": 1966000000,
"services": 1307100000,
"total_revenue": 8352100000
},
"revenue_by_geography": {
"united_states": 5589400000,
"outside_united_states": 2762700000
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2023-01-01",
"period_end": "2023-12-31",
"period_type": "fiscal year",
"source_accession": "0001035267-26-000010",
"income_statement": {
"product_revenue": 5956300000,
"service_revenue": 1167800000,
"total_revenue": 7124100000,
"product_cost_of_revenue": 2041800000,
"service_cost_of_revenue": 352800000,
"total_cost_of_revenue": 2394600000,
"gross_profit": 4729500000,
"selling_general_and_administrative": 1963900000,
"research_and_development": 998800000,
"total_operating_expenses": 2962700000,
"income_from_operations": 1766800000,
"interest_and_other_income_net": 192100000,
"income_before_taxes": 1958900000,
"income_tax_expense": 141600000,
"net_income": 1817300000,
"net_income_attributable_to_noncontrolling_interest": 19300000,
"net_income_attributable_to_intuitive_surgical": 1798000000,
"basic_eps": 5.12,
"diluted_eps": 5.03,
"basic_shares": 351200000,
"diluted_shares": 357400000
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 401600000,
"amortization_of_intangible_and_other_assets": 53200000,
"deferred_income_taxes": -280800000,
"share_based_compensation": 592800000,
"operating_cash_flow": 1813800000,
"purchases_of_investments": -2207400000,
"proceeds_from_sales_of_investments": 230300000,
"proceeds_from_maturities_of_investments": 2690100000,
"capital_expenditures": -1064200000,
"acquisitions_net_of_cash_intellectual_property_and_other_investing": -8900000,
"net_cash_from_investing_activities": -360100000,
"proceeds_from_employee_stock_plans": 296300000,
"taxes_paid_for_net_share_settlement_of_equity_awards": -164700000,
"repurchases_of_common_stock": -416300000,
"net_cash_from_financing_activities": -287600000,
"effect_of_exchange_rate_changes": 3300000,
"net_change_in_cash_cash_equivalents_and_restricted_cash": 1169400000,
"cash_cash_equivalents_and_restricted_cash_end_of_period": 2770100000,
"free_cash_flow": 749600000
},
"revenue_by_type": {
"instruments_and_accessories": 4276600000,
"systems": 1679700000,
"services": 1167800000,
"total_revenue": 7124100000
},
"revenue_by_geography": {
"united_states": 4688600000,
"outside_united_states": 2435500000
}
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 3,
"label": "Q3 FY2026",
"period_start": "2026-07-01",
"period_end": "2026-09-30",
"period_type": "three months",
"source_accession": "0001035267-26-000071",
"income_statement": {
"product_revenue": 2566500000,
"service_revenue": 482200000,
"total_revenue": 3048700000,
"product_cost_of_revenue": 797700000,
"service_cost_of_revenue": 166700000,
"total_cost_of_revenue": 964400000,
"gross_profit": 2084300000,
"selling_general_and_administrative": 633400000,
"antitrust_class_action_litigation_settlement": 450000000,
"research_and_development": 408300000,
"total_operating_expenses": 1491700000,
"income_from_operations": 592600000,
"interest_and_other_income_net": 75800000,
"income_before_taxes": 668400000,
"income_tax_expense": 144000000,
"net_income": 524400000,
"net_income_attributable_to_noncontrolling_interest": 1600000,
"net_income_attributable_to_intuitive_surgical": 522800000,
"basic_eps": 1.5,
"diluted_eps": 1.49,
"basic_shares": 349000000,
"diluted_shares": 351600000
},
"balance_sheet": {
"cash_and_cash_equivalents": 2978100000,
"short_term_investments": 1064400000,
"accounts_receivable_net": 1721300000,
"inventory": 2128200000,
"prepaids_and_other_current_assets": 536300000,
"total_current_assets": 8428300000,
"property_plant_and_equipment_net": 5676200000,
"long_term_investments": 2757900000,
"deferred_tax_assets": 719700000,
"intangible_and_other_assets_net": 1209200000,
"goodwill": 557800000,
"total_assets": 19349100000,
"accounts_payable": 279500000,
"accrued_compensation_and_employee_benefits": 505900000,
"deferred_revenue": 541200000,
"other_accrued_liabilities": 1206400000,
"total_current_liabilities": 2533000000,
"other_long_term_liabilities": 698300000,
"total_liabilities": 3231300000,
"additional_paid_in_capital": 11521100000,
"retained_earnings": 4525100000,
"accumulated_other_comprehensive_income_loss": -60300000,
"total_intuitive_surgical_stockholders_equity": 15986200000,
"noncontrolling_interest_in_joint_venture": 131600000,
"total_stockholders_equity": 16117800000,
"common_shares_outstanding": 346600000,
"cash_cash_equivalents_and_investments": 6800400000
},
"revenue_by_type": {
"instruments_and_accessories": 1797400000,
"systems": 769100000,
"services": 482200000,
"total_revenue": 3048700000
},
"revenue_by_geography": {
"united_states": 2063000000,
"outside_united_states": 985700000
},
"shareholder_returns": {
"shares_repurchased": 7800000,
"average_price_per_share_repurchased": 377.01,
"aggregate_cost_of_shares_repurchased": 2939800000
},
"non_gaap": {
"non_gaap_gross_profit": 2129600000,
"non_gaap_income_from_operations": 1269700000,
"non_gaap_net_income_attributable_to_intuitive_surgical": 1054500000,
"non_gaap_diluted_eps": 3
},
"non_gaap_source_accession": "0001035267-26-000067"
},
{
"fiscal_year": 2025,
"fiscal_quarter": 3,
"label": "Q3 FY2025",
"period_start": "2025-07-01",
"period_end": "2025-09-30",
"period_type": "three months",
"source_accession": "0001035267-26-000071",
"income_statement": {
"product_revenue": 2109200000,
"service_revenue": 395900000,
"total_revenue": 2505100000,
"product_cost_of_revenue": 699400000,
"service_cost_of_revenue": 143300000,
"total_cost_of_revenue": 842700000,
"gross_profit": 1662400000,
"selling_general_and_administrative": 573300000,
"antitrust_class_action_litigation_settlement": 0,
"research_and_development": 329400000,
"total_operating_expenses": 902700000,
"income_from_operations": 759700000,
"interest_and_other_income_net": 95500000,
"income_before_taxes": 855200000,
"income_tax_expense": 146000000,
"net_income": 709200000,
"net_income_attributable_to_noncontrolling_interest": 4800000,
"net_income_attributable_to_intuitive_surgical": 704400000,
"basic_eps": 1.98,
"diluted_eps": 1.95,
"basic_shares": 356600000,
"diluted_shares": 361800000
},
"revenue_by_type": {
"instruments_and_accessories": 1518800000,
"systems": 590400000,
"services": 395900000,
"total_revenue": 2505100000
},
"revenue_by_geography": {
"united_states": 1717600000,
"outside_united_states": 787500000
},
"shareholder_returns": {
"shares_repurchased": 4000000,
"average_price_per_share_repurchased": 479.6,
"aggregate_cost_of_shares_repurchased": 1919600000
},
"non_gaap": {
"non_gaap_gross_profit": 1703800000,
"non_gaap_income_from_operations": 975900000,
"non_gaap_net_income_attributable_to_intuitive_surgical": 867200000,
"non_gaap_diluted_eps": 2.4
},
"balance_sheet": {
"total_intuitive_surgical_stockholders_equity": 16929700000,
"noncontrolling_interest_in_joint_venture": 112400000,
"total_stockholders_equity": 17042100000,
"common_shares_outstanding": 354900000,
"additional_paid_in_capital": 10478800000,
"retained_earnings": 6424000000,
"accumulated_other_comprehensive_income_loss": 26500000
},
"non_gaap_source_accession": "0001035267-26-000067",
"balance_sheet_source": "The Q3 2026 10-Q prints no September 30, 2025 balance sheet; the equity figures and shares outstanding shown for Q3 FY2025 are the September 30, 2025 ending balances in that 10-Q's stockholders' equity note (Note 9)."
}
],
"year_to_date": {
"fiscal_year": 2026,
"label": "Nine months ended September 30, 2026",
"period_start": "2026-01-01",
"period_end": "2026-09-30",
"period_type": "nine months",
"source_accession": "0001035267-26-000071",
"prior_year_comparative": {
"fiscal_year": 2025,
"label": "Nine months ended September 30, 2025",
"period_start": "2025-01-01",
"period_end": "2025-09-30",
"period_type": "nine months",
"source_accession": "0001035267-26-000071",
"income_statement": {
"product_revenue": 6048400000,
"service_revenue": 1150100000,
"total_revenue": 7198500000,
"product_cost_of_revenue": 2056300000,
"service_cost_of_revenue": 404200000,
"total_cost_of_revenue": 2460500000,
"gross_profit": 4738000000,
"selling_general_and_administrative": 1697900000,
"antitrust_class_action_litigation_settlement": 0,
"research_and_development": 958900000,
"total_operating_expenses": 2656800000,
"income_from_operations": 2081200000,
"interest_and_other_income_net": 274600000,
"income_before_taxes": 2355800000,
"income_tax_expense": 278700000,
"net_income": 2077100000,
"net_income_attributable_to_noncontrolling_interest": 15900000,
"net_income_attributable_to_intuitive_surgical": 2061200000,
"basic_eps": 5.77,
"diluted_eps": 5.67,
"basic_shares": 357500000,
"diluted_shares": 363500000
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 446300000,
"amortization_of_intangible_and_other_assets": 37300000,
"deferred_income_taxes": 58600000,
"share_based_compensation": 584900000,
"operating_cash_flow": 2138000000,
"purchases_of_investments": -790900000,
"proceeds_from_sales_of_investments": 249100000,
"proceeds_from_maturities_of_investments": 1795500000,
"proceeds_from_sale_of_assets": 0,
"capital_expenditures": -377300000,
"acquisitions_net_of_cash_intellectual_property_and_other_investing": -1200000,
"net_cash_from_investing_activities": 875200000,
"proceeds_from_employee_stock_plans": 273700000,
"taxes_paid_for_net_share_settlement_of_equity_awards": -406000000,
"repurchases_of_common_stock": -2094300000,
"other_financing_activities": 0,
"net_cash_from_financing_activities": -2226600000,
"effect_of_exchange_rate_changes": 500000,
"net_change_in_cash_cash_equivalents_and_restricted_cash": 787100000,
"cash_cash_equivalents_and_restricted_cash_end_of_period": 2849500000,
"free_cash_flow": 1760700000
},
"revenue_by_type": {
"instruments_and_accessories": 4360600000,
"systems": 1687800000,
"services": 1150100000,
"total_revenue": 7198500000
},
"revenue_by_geography": {
"united_states": 4885200000,
"outside_united_states": 2313300000
},
"shareholder_returns": {
"shares_repurchased": 4400000,
"average_price_per_share_repurchased": 482.66,
"aggregate_cost_of_shares_repurchased": 2100600000
},
"non_gaap": {
"non_gaap_gross_profit": 4857500000,
"non_gaap_income_from_operations": 2690000000,
"non_gaap_net_income_attributable_to_intuitive_surgical": 2326600000,
"non_gaap_diluted_eps": 6.4
},
"non_gaap_source_accession": "0001035267-26-000067"
},
"income_statement": {
"product_revenue": 7323500000,
"service_revenue": 1388300000,
"total_revenue": 8711800000,
"product_cost_of_revenue": 2354700000,
"service_cost_of_revenue": 481900000,
"total_cost_of_revenue": 2836600000,
"gross_profit": 5875200000,
"selling_general_and_administrative": 1864600000,
"antitrust_class_action_litigation_settlement": 450000000,
"research_and_development": 1140800000,
"total_operating_expenses": 3455400000,
"income_from_operations": 2419800000,
"interest_and_other_income_net": 243600000,
"income_before_taxes": 2663400000,
"income_tax_expense": 489800000,
"net_income": 2173600000,
"net_income_attributable_to_noncontrolling_interest": 11200000,
"net_income_attributable_to_intuitive_surgical": 2162400000,
"basic_eps": 6.13,
"diluted_eps": 6.07,
"basic_shares": 352600000,
"diluted_shares": 356200000
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": 559000000,
"amortization_of_intangible_and_other_assets": 85000000,
"deferred_income_taxes": 315900000,
"share_based_compensation": 632000000,
"operating_cash_flow": 3197000000,
"purchases_of_investments": -1460300000,
"proceeds_from_sales_of_investments": 1845100000,
"proceeds_from_maturities_of_investments": 1373500000,
"proceeds_from_sale_of_assets": 46000000,
"capital_expenditures": -329000000,
"acquisitions_net_of_cash_intellectual_property_and_other_investing": -518600000,
"net_cash_from_investing_activities": 956700000,
"proceeds_from_employee_stock_plans": 283800000,
"taxes_paid_for_net_share_settlement_of_equity_awards": -378500000,
"repurchases_of_common_stock": -4419200000,
"other_financing_activities": -21300000,
"net_cash_from_financing_activities": -4535200000,
"effect_of_exchange_rate_changes": -3500000,
"net_change_in_cash_cash_equivalents_and_restricted_cash": -385000000,
"cash_cash_equivalents_and_restricted_cash_end_of_period": 3022400000,
"free_cash_flow": 2868000000
},
"revenue_by_type": {
"instruments_and_accessories": 5218700000,
"systems": 2104800000,
"services": 1388300000,
"total_revenue": 8711800000
},
"revenue_by_geography": {
"united_states": 5779500000,
"outside_united_states": 2932300000
},
"shareholder_returns": {
"shares_repurchased": 11000000,
"average_price_per_share_repurchased": 405.51,
"aggregate_cost_of_shares_repurchased": 4446300000
},
"non_gaap": {
"non_gaap_gross_profit": 6032600000,
"non_gaap_income_from_operations": 3564500000,
"non_gaap_net_income_attributable_to_intuitive_surgical": 2957700000,
"non_gaap_diluted_eps": 8.3
},
"non_gaap_source_accession": "0001035267-26-000067"
},
"trailing_twelve_months": {
"label": "Twelve months ended September 30, 2026",
"period_start": "2025-10-01",
"period_end": "2026-09-30",
"period_type": "trailing twelve months",
"source_accession": "0001035267-26-000071",
"derived_from_accessions": [
"0001035267-26-000010",
"0001035267-26-000071"
],
"income_statement": {
"product_revenue": 9767700000,
"service_revenue": 1810300000,
"total_revenue": 11578000000,
"product_cost_of_revenue": 3164500000,
"service_cost_of_revenue": 634000000,
"total_cost_of_revenue": 3798500000,
"gross_profit": 7779500000,
"selling_general_and_administrative": 2551700000,
"research_and_development": 1493700000,
"total_operating_expenses": 4495400000,
"income_from_operations": 3284100000,
"interest_and_other_income_net": 334900000,
"income_before_taxes": 3619000000,
"income_tax_expense": 645900000,
"net_income": 2973100000,
"net_income_attributable_to_noncontrolling_interest": 15900000,
"net_income_attributable_to_intuitive_surgical": 2957200000,
"antitrust_class_action_litigation_settlement": 450000000
},
"cash_flow": {
"operating_cash_flow": 4089500000,
"capital_expenditures": -491500000,
"share_based_compensation": 835300000,
"repurchases_of_common_stock": -4620200000,
"free_cash_flow": 3598000000
},
"revenue_by_type": {
"instruments_and_accessories": 6877000000,
"systems": 2890700000,
"services": 1810300000,
"total_revenue": 11578000000
}
},
"notes": [
"Annual figures for FY2023, FY2024 and FY2025 are from the FY2025 Form 10-K (accession 0001035267-26-000010), which prints three years of income and cash flow statements and two year-end balance sheets (December 31, 2025 and 2024); FY2023 therefore carries no balance sheet.",
"Quarterly figures for the three months ended September 30, 2026 and 2025, the nine-month year-to-date figures and the September 30, 2026 balance sheet are from the Q3 2026 Form 10-Q (accession 0001035267-26-000071). The December 31, 2025 balance sheet column the 10-Q reprints matches the 10-K line for line.",
"Q3 2026 results include a $450.0 million pre-tax charge for the settlement of the antitrust class action litigation (\"In re: da Vinci Surgical Robot Antitrust Litigation\"), which the 10-Q presents as a separate operating-expense line. The earnings release instead includes it within selling, general and administrative expense, which it reports as $1,083.4 million for the quarter ($633.4 million plus the $450.0 million settlement). The release states the charge was $347 million net of tax, or $0.99 per diluted share, and that the settlement remains subject to court approval. This charge is why Q3 2026 income from operations ($592.6 million) fell from Q3 2025 ($759.7 million) while revenue rose 22%.",
"The 10-Q prints cash flows for the nine months only, so the quarterly entries carry no cash flow figures; nine-month cash flows are in the year-to-date block.",
"The balance sheets present no debt or borrowings line, so no total-debt figure is shown. The company paid no dividends; the only dividend line on the cash flow statement is the joint venture's $8.0 million payment to its noncontrolling holder in FY2024.",
"Cash flow outflows are stored as negative numbers, as the statements print them in parentheses.",
"The trailing-twelve-month block is computed as FY2025 plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025; per-share figures and share counts are not computed for it. Its SG&A excludes the $450.0 million settlement, which is shown on its own line.",
"Non-GAAP figures for Q3 2026, Q3 2025 and both nine-month periods are the company's own, from the GAAP to non-GAAP reconciliation in its Q3 2026 earnings release (accession 0001035267-26-000067); they are not GAAP measures."
],
"uncertainties": [
"Three-month cash flow figures for Q3 2026 and Q3 2025 (operating cash flow, capital expenditures, free cash flow) are not available: the Q3 2026 10-Q prints only nine-month cash flows, and the six-month figures needed to difference them are in the Q2 2026 10-Q, which is not among the filings read for this page.",
"The FY2025 10-K has no separate litigation-settlement line, so FY2025 SG&A includes whatever litigation charges arose that year; the earnings release attributes $454.9 million of Q3 2026 litigation charges to SG&A, of which $450.0 million is the antitrust settlement shown separately in the 10-Q."
],
"definitions": {
"net_income": "Consolidated net income, including the share earned by the noncontrolling interest in the company's joint venture with Fosun Pharma. Earnings per share are struck on net_income_attributable_to_intuitive_surgical.",
"antitrust_class_action_litigation_settlement": "The $450.0 million charge for the settlement of the antitrust class action litigation, which the Q3 2026 10-Q presents as its own operating-expense line. Zero where the 10-Q prints a dash; not presented in the FY2025 10-K.",
"free_cash_flow": "Net cash provided by operating activities less purchases of property, plant, and equipment. Computed here from the cash flow statement; it is not a figure the company reports.",
"capital_expenditures": "Purchases of property, plant, and equipment as printed on the cash flow statement (shown as a negative outflow).",
"cash_cash_equivalents_and_investments": "Cash and cash equivalents plus short-term and long-term investments, summed from the balance sheet. The company's Q3 2026 earnings release prints the same total: $6,800.4 million at September 30, 2026 and $9,034.1 million at December 31, 2025.",
"common_shares_outstanding": "Common shares issued and outstanding at the period end, from the stockholders' equity statement.",
"revenue_by_type": "Revenue disaggregated by type in the revenue note: instruments and accessories plus systems make up product revenue; services equals service revenue.",
"non_gaap": "The company's own non-GAAP measures from its Q3 2026 earnings release (Exhibit 99.1 to the Form 8-K, accession 0001035267-26-000067). They exclude share-based compensation and long-term incentive plan expense, amortization of intangible assets, litigation charges (including the $450 million antitrust settlement), acquisition-related items, gains on sale of businesses and assets, gains or losses on strategic investments and tax adjustments, as the release defines them.",
"trailing_twelve_months": "FY2025 from the FY2025 10-K plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025, both from the Q3 2026 10-Q."
},
"headline": {
"period": "Q3 FY2026",
"period_end_words": "September 30, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 3048700000,
"text": "$3.05 billion",
"exact": "$3,048,700,000",
"compact": "$3.05B",
"abs": "$3.05 billion",
"prior_value": 2505100000,
"prior": "$2.51 billion",
"priorabs": "$2.51 billion",
"yoy": "up 21.7%",
"source": {
"array": "quarterly",
"field": "income_statement.total_revenue",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-30",
"period_start": "2026-07-01",
"span_days": 91,
"source_accession": "0001035267-26-000071",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-30",
"prior_period_start": "2025-07-01",
"prior_span_days": 91,
"prior_source_accession": "0001035267-26-000071",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": 522800000,
"text": "$522.8 million",
"exact": "$522,800,000",
"compact": "$522.80M",
"abs": "$522.8 million",
"prior_value": 704400000,
"prior": "$704.4 million",
"priorabs": "$704.4 million",
"yoy": "down 25.8%",
"source": {
"array": "quarterly",
"field": "income_statement.net_income_attributable_to_intuitive_surgical",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-30",
"period_start": "2026-07-01",
"span_days": 91,
"source_accession": "0001035267-26-000071",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-30",
"prior_period_start": "2025-07-01",
"prior_span_days": 91,
"prior_source_accession": "0001035267-26-000071",
"gap_days": 365
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 1.49,
"text": "$1.49",
"exact": "$1.49",
"compact": "$1.49",
"abs": "$1.49",
"prior_value": 1.95,
"prior": "$1.95",
"priorabs": "$1.95",
"yoy": "down 23.6%",
"source": {
"array": "quarterly",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-30",
"period_start": "2026-07-01",
"span_days": 91,
"source_accession": "0001035267-26-000071",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-30",
"prior_period_start": "2025-07-01",
"prior_span_days": 91,
"prior_source_accession": "0001035267-26-000071",
"gap_days": 365
}
},
{
"label": "Antitrust settlement charge",
"format": "usd",
"value": 450000000,
"text": "$450 million",
"exact": "$450,000,000",
"compact": "$450.00M",
"abs": "$450 million",
"prior_value": null,
"prior": null,
"priorabs": null,
"yoy": null,
"source": {
"array": "quarterly",
"field": "income_statement.antitrust_class_action_litigation_settlement",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-30",
"period_start": "2026-07-01",
"span_days": 91,
"source_accession": "0001035267-26-000071"
}
},
{
"label": "Non-GAAP diluted EPS",
"format": "eps",
"value": 3,
"text": "$3.00",
"exact": "$3.00",
"compact": "$3.00",
"abs": "$3.00",
"prior_value": 2.4,
"prior": "$2.40",
"priorabs": "$2.40",
"yoy": "up 25.0%",
"source": {
"array": "quarterly",
"field": "non_gaap.non_gaap_diluted_eps",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-30",
"period_start": "2026-07-01",
"span_days": 91,
"source_accession": "0001035267-26-000067",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-30",
"prior_period_start": "2025-07-01",
"prior_span_days": 91,
"prior_source_accession": "0001035267-26-000067",
"gap_days": 365
}
}
],
"summary": "Intuitive Surgical reported revenue of $3.05 billion for Q3 FY2026, the quarter ended September 30, 2026, up 21.7% from a year earlier, with instruments and accessories, systems and services all growing. Net income attributable to Intuitive was $522.8 million, or $1.49 per diluted share, down 25.8% from $704.4 million, because the quarter carried a $450 million charge for its agreement to settle a hospital antitrust class action, which still needs court approval. On the company's own non-GAAP basis, which excludes the charge, diluted earnings per share were $3.00, up 25.0% from $2.40.",
"qa": [
{
"q": "How much revenue did Intuitive Surgical report in Q3 FY2026?",
"a": "Intuitive Surgical reported revenue of $3.05 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 21.7% from $2.51 billion in the same quarter a year earlier."
},
{
"q": "Why did Intuitive Surgical's earnings fall in Q3 FY2026?",
"a": "Intuitive Surgical's net income attributable to the company fell to $522.8 million in Q3 FY2026, down 25.8% from $704.4 million a year earlier, and diluted earnings per share fell to $1.49 from $1.95. The decline reflects a $450 million operating-expense charge, recorded in the quarter, for settling a hospital antitrust class action, while revenue was up 21.7% from a year earlier."
},
{
"q": "What is Intuitive Surgical's antitrust class action settlement?",
"a": "Intuitive Surgical agreed after the quarter to make a one-time payment of $450 million to settle the hospital class action known as In re: da Vinci Surgical Robot Antitrust Litigation, with agreed injunctive relief and no admission of liability. The company recorded the full amount as an operating-expense charge and a liability for the quarter ended September 30, 2026, and the settlement still needs preliminary and final court approval."
},
{
"q": "What was Intuitive Surgical's non-GAAP EPS in Q3 FY2026?",
"a": "Intuitive Surgical reported non-GAAP diluted earnings per share of $3.00 for Q3 FY2026, up 25.0% from $2.40 a year earlier, compared with GAAP diluted earnings per share of $1.49. The company's non-GAAP measure excludes items including the antitrust settlement charge, share-based compensation and amortization of intangible assets."
}
]
},
"company_details": {
"Name": "Intuitive Surgical Inc",
"Ticker": "ISRG",
"CIK": "0001035267",
"Exchange": "Nasdaq",
"State": "California",
"Incorporation": "Delaware",
"SIC": "3842",
"Office": "Industrial Applications and Services",
"Industry": "Orthopedic, Prosthetic & Surgical Appliances & Supplies"
},
"next_filing": {
"predicted_date": "2027-02-02",
"predicted_type": "10-K"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q3",
"tag": "FY26Q3",
"period_end": "2026-09-30",
"form": "10-Q",
"accession": "0001035267-26-000071",
"fiscal_year_end": "1231",
"source": "facts"
},
"source_filings": [
{
"role": "annual",
"current": false,
"form": "10-K",
"fiscal_year": 2025,
"fiscal_period": "FY",
"tag": "FY25",
"period_end": "2025-12-31",
"filed": "2026-02-03",
"accession": "0001035267-26-000010",
"url": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm",
"source": "reported"
},
{
"role": "quarterly",
"current": true,
"form": "10-Q",
"fiscal_year": 2026,
"fiscal_period": "Q3",
"tag": "FY26Q3",
"period_end": "2026-09-30",
"filed": "2026-10-21",
"accession": "0001035267-26-000071",
"url": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm",
"source": "facts"
}
],
"figure_sources": {
"about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '<document>#<anchor>', and the link is documents[<document>] + '#<anchor>': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.",
"documents": {
"d1": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000010/isrg-20251231.htm",
"d2": "https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm"
},
"annual": [
{
"period_end": "2025-12-31",
"income_statement": {
"product_revenue": "d1#f-133",
"service_revenue": "d1#f-136",
"total_revenue": "d1#f-139",
"product_cost_of_revenue": "d1#f-142",
"service_cost_of_revenue": "d1#f-145",
"total_cost_of_revenue": "d1#f-148",
"gross_profit": "d1#f-151",
"selling_general_and_administrative": "d1#f-154",
"research_and_development": "d1#f-157",
"total_operating_expenses": "d1#f-160",
"income_from_operations": "d1#f-163",
"interest_and_other_income_net": "d1#f-166",
"income_before_taxes": "d1#f-169",
"income_tax_expense": "d1#f-172",
"net_income": "d1#f-175",
"net_income_attributable_to_noncontrolling_interest": "d1#f-344",
"net_income_attributable_to_intuitive_surgical": "d1#f-181",
"basic_eps": "d1#f-184",
"diluted_eps": "d1#f-187",
"basic_shares": "d1#f-190",
"diluted_shares": "d1#f-193"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d1#f-56",
"short_term_investments": "d1#f-58",
"accounts_receivable_net": "d1#f-62",
"inventory": "d1#f-64",
"prepaids_and_other_current_assets": "d1#f-67",
"total_current_assets": "d1#f-69",
"property_plant_and_equipment_net": "d1#f-71",
"deferred_tax_assets": "d1#f-75",
"intangible_and_other_assets_net": "d1#f-77",
"goodwill": "d1#f-79",
"total_assets": "d1#f-81",
"accounts_payable": "d1#f-83",
"accrued_compensation_and_employee_benefits": "d1#f-85",
"deferred_revenue": "d1#f-87",
"other_accrued_liabilities": "d1#f-89",
"total_current_liabilities": "d1#f-91",
"other_long_term_liabilities": "d1#f-93",
"total_liabilities": "d1#f-95",
"additional_paid_in_capital": "d1#f-119",
"retained_earnings": "d1#f-121",
"accumulated_other_comprehensive_income_loss": "d1#f-123",
"total_intuitive_surgical_stockholders_equity": "d1#f-125",
"noncontrolling_interest_in_joint_venture": "d1#f-127",
"total_stockholders_equity": "d1#f-129",
"common_shares_outstanding": "d1#f-113",
"cash_cash_equivalents_and_investments": "d1#f-611"
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": "d1#f-356",
"amortization_of_intangible_and_other_assets": "d1#f-359",
"deferred_income_taxes": "d1#f-368",
"share_based_compensation": "d1#f-371",
"operating_cash_flow": "d1#f-395",
"purchases_of_investments": "d1#f-398",
"proceeds_from_sales_of_investments": "d1#f-401",
"proceeds_from_maturities_of_investments": "d1#f-404",
"capital_expenditures": "d1#f-407",
"acquisitions_net_of_cash_intellectual_property_and_other_investing": "d1#f-410",
"net_cash_from_investing_activities": "d1#f-413",
"proceeds_from_employee_stock_plans": "d1#f-416",
"taxes_paid_for_net_share_settlement_of_equity_awards": "d1#f-419",
"repurchases_of_common_stock": "d1#f-422",
"net_cash_from_financing_activities": "d1#f-431",
"effect_of_exchange_rate_changes": "d1#f-434",
"net_change_in_cash_cash_equivalents_and_restricted_cash": "d1#f-437",
"cash_cash_equivalents_and_restricted_cash_end_of_period": "d1#f-443"
},
"revenue_by_type": {
"instruments_and_accessories": "d1#f-888",
"systems": "d1#f-891",
"services": "d1#f-894",
"total_revenue": "d1#f-897"
},
"revenue_by_geography": {
"united_states": "d1#f-873",
"outside_united_states": "d1#f-885"
}
},
{
"period_end": "2024-12-31",
"income_statement": {
"product_revenue": "d1#f-134",
"service_revenue": "d1#f-137",
"total_revenue": "d1#f-140",
"product_cost_of_revenue": "d1#f-143",
"service_cost_of_revenue": "d1#f-146",
"total_cost_of_revenue": "d1#f-149",
"gross_profit": "d1#f-152",
"selling_general_and_administrative": "d1#f-155",
"research_and_development": "d1#f-158",
"total_operating_expenses": "d1#f-161",
"income_from_operations": "d1#f-164",
"interest_and_other_income_net": "d1#f-167",
"income_before_taxes": "d1#f-170",
"income_tax_expense": "d1#f-173",
"net_income": "d1#f-176",
"net_income_attributable_to_noncontrolling_interest": "d1#f-305",
"net_income_attributable_to_intuitive_surgical": "d1#f-182",
"basic_eps": "d1#f-185",
"diluted_eps": "d1#f-188",
"basic_shares": "d1#f-191",
"diluted_shares": "d1#f-194"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d1#f-57",
"short_term_investments": "d1#f-59",
"accounts_receivable_net": "d1#f-63",
"inventory": "d1#f-65",
"prepaids_and_other_current_assets": "d1#f-68",
"total_current_assets": "d1#f-70",
"property_plant_and_equipment_net": "d1#f-72",
"long_term_investments": "d1#f-74",
"deferred_tax_assets": "d1#f-76",
"intangible_and_other_assets_net": "d1#f-78",
"goodwill": "d1#f-80",
"total_assets": "d1#f-82",
"accounts_payable": "d1#f-84",
"accrued_compensation_and_employee_benefits": "d1#f-86",
"deferred_revenue": "d1#f-88",
"other_accrued_liabilities": "d1#f-90",
"total_current_liabilities": "d1#f-92",
"other_long_term_liabilities": "d1#f-94",
"total_liabilities": "d1#f-96",
"additional_paid_in_capital": "d1#f-120",
"retained_earnings": "d1#f-122",
"accumulated_other_comprehensive_income_loss": "d1#f-124",
"total_intuitive_surgical_stockholders_equity": "d1#f-126",
"noncontrolling_interest_in_joint_venture": "d1#f-128",
"total_stockholders_equity": "d1#f-130",
"common_shares_outstanding": "d1#f-115",
"cash_cash_equivalents_and_investments": "d1#f-675"
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": "d1#f-357",
"amortization_of_intangible_and_other_assets": "d1#f-360",
"deferred_income_taxes": "d1#f-369",
"share_based_compensation": "d1#f-372",
"operating_cash_flow": "d1#f-396",
"purchases_of_investments": "d1#f-399",
"proceeds_from_sales_of_investments": "d1#f-402",
"proceeds_from_maturities_of_investments": "d1#f-405",
"capital_expenditures": "d1#f-408",
"acquisitions_net_of_cash_intellectual_property_and_other_investing": "d1#f-411",
"net_cash_from_investing_activities": "d1#f-414",
"proceeds_from_employee_stock_plans": "d1#f-417",
"taxes_paid_for_net_share_settlement_of_equity_awards": "d1#f-420",
"net_cash_from_financing_activities": "d1#f-432",
"effect_of_exchange_rate_changes": "d1#f-435",
"net_change_in_cash_cash_equivalents_and_restricted_cash": "d1#f-438",
"cash_cash_equivalents_and_restricted_cash_end_of_period": "d1#f-440"
},
"revenue_by_type": {
"instruments_and_accessories": "d1#f-889",
"systems": "d1#f-892",
"services": "d1#f-895",
"total_revenue": "d1#f-898"
},
"revenue_by_geography": {
"united_states": "d1#f-874",
"outside_united_states": "d1#f-886"
}
},
{
"period_end": "2023-12-31",
"income_statement": {
"product_revenue": "d1#f-135",
"service_revenue": "d1#f-138",
"total_revenue": "d1#f-141",
"product_cost_of_revenue": "d1#f-144",
"service_cost_of_revenue": "d1#f-147",
"total_cost_of_revenue": "d1#f-150",
"gross_profit": "d1#f-153",
"selling_general_and_administrative": "d1#f-156",
"research_and_development": "d1#f-159",
"total_operating_expenses": "d1#f-162",
"income_from_operations": "d1#f-165",
"interest_and_other_income_net": "d1#f-168",
"income_before_taxes": "d1#f-171",
"income_tax_expense": "d1#f-174",
"net_income": "d1#f-177",
"net_income_attributable_to_noncontrolling_interest": "d1#f-274",
"net_income_attributable_to_intuitive_surgical": "d1#f-183",
"basic_eps": "d1#f-186",
"diluted_eps": "d1#f-189",
"basic_shares": "d1#f-192",
"diluted_shares": "d1#f-195"
},
"cash_flow": {
"depreciation_and_loss_on_disposal_of_property_plant_and_equipment": "d1#f-358",
"amortization_of_intangible_and_other_assets": "d1#f-361",
"deferred_income_taxes": "d1#f-370",
"share_based_compensation": "d1#f-373",
"operating_cash_flow": "d1#f-397",
"purchases_of_investments": "d1#f-400",
"proceeds_from_sales_of_investments": "d1#f-403",
"proceeds_from_maturities_of_investments": "d1#f-406",
"capital_expenditures": "d1#f-409",
"acquisitions_net_of_cash_intellectual_property_and_other_investing": "d1#f-412",
"net_cash_from_investing_activities": "d1#f-415",
"proceeds_from_employee_stock_plans": "d1#f-418",
"taxes_paid_for_net_share_settlement_of_equity_awards": "d1#f-421",
"repurchases_of_common_stock": "d1#f-424",
"net_cash_from_financing_activities": "d1#f-433",
"effect_of_exchange_rate_changes": "d1#f-436",
"net_change_in_cash_cash_equivalents_and_restricted_cash": "d1#f-439",
"cash_cash_equivalents_and_restricted_cash_end_of_period": "d1#f-441"
},
"revenue_by_type": {
"instruments_and_accessories": "d1#f-890",
"systems": "d1#f-893",
"services": "d1#f-896",
"total_revenue": "d1#f-899"
},
"revenue_by_geography": {
"united_states": "d1#f-875",
"outside_united_states": "d1#f-887"
}
}
],
"quarterly": [
{
"period_end": "2026-09-30",
"income_statement": {
"product_revenue": "d2#f-104",
"service_revenue": "d2#f-108",
"total_revenue": "d2#f-112",
"product_cost_of_revenue": "d2#f-116",
"service_cost_of_revenue": "d2#f-120",
"total_cost_of_revenue": "d2#f-124",
"gross_profit": "d2#f-128",
"selling_general_and_administrative": "d2#f-132",
"antitrust_class_action_litigation_settlement": "d2#f-136",
"research_and_development": "d2#f-140",
"total_operating_expenses": "d2#f-144",
"income_from_operations": "d2#f-148",
"interest_and_other_income_net": "d2#f-152",
"income_before_taxes": "d2#f-156",
"income_tax_expense": "d2#f-160",
"net_income": "d2#f-164",
"net_income_attributable_to_noncontrolling_interest": "d2#f-809",
"net_income_attributable_to_intuitive_surgical": "d2#f-172",
"basic_eps": "d2#f-176",
"diluted_eps": "d2#f-180",
"basic_shares": "d2#f-184",
"diluted_shares": "d2#f-188"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d2#f-30",
"short_term_investments": "d2#f-32",
"accounts_receivable_net": "d2#f-34",
"inventory": "d2#f-36",
"prepaids_and_other_current_assets": "d2#f-38",
"total_current_assets": "d2#f-40",
"property_plant_and_equipment_net": "d2#f-42",
"deferred_tax_assets": "d2#f-46",
"intangible_and_other_assets_net": "d2#f-48",
"goodwill": "d2#f-50",
"total_assets": "d2#f-52",
"accounts_payable": "d2#f-54",
"accrued_compensation_and_employee_benefits": "d2#f-56",
"deferred_revenue": "d2#f-58",
"other_accrued_liabilities": "d2#f-60",
"total_current_liabilities": "d2#f-62",
"other_long_term_liabilities": "d2#f-64",
"total_liabilities": "d2#f-66",
"additional_paid_in_capital": "d2#f-90",
"retained_earnings": "d2#f-92",
"accumulated_other_comprehensive_income_loss": "d2#f-94",
"total_intuitive_surgical_stockholders_equity": "d2#f-96",
"noncontrolling_interest_in_joint_venture": "d2#f-98",
"total_stockholders_equity": "d2#f-100",
"common_shares_outstanding": "d2#f-84",
"cash_cash_equivalents_and_investments": "d2#f-349"
},
"revenue_by_type": {
"instruments_and_accessories": "d2#f-588",
"systems": "d2#f-592",
"services": "d2#f-596",
"total_revenue": "d2#f-600"
},
"revenue_by_geography": {
"united_states": "d2#f-568",
"outside_united_states": "d2#f-584"
},
"shareholder_returns": {
"shares_repurchased": "d2#f-795",
"aggregate_cost_of_shares_repurchased": "d2#f-800"
}
},
{
"period_end": "2025-09-30",
"income_statement": {
"product_revenue": "d2#f-105",
"service_revenue": "d2#f-109",
"total_revenue": "d2#f-113",
"product_cost_of_revenue": "d2#f-117",
"service_cost_of_revenue": "d2#f-121",
"total_cost_of_revenue": "d2#f-125",
"gross_profit": "d2#f-129",
"selling_general_and_administrative": "d2#f-133",
"research_and_development": "d2#f-141",
"total_operating_expenses": "d2#f-145",
"income_from_operations": "d2#f-149",
"interest_and_other_income_net": "d2#f-153",
"income_before_taxes": "d2#f-157",
"income_tax_expense": "d2#f-161",
"net_income": "d2#f-165",
"net_income_attributable_to_noncontrolling_interest": "d2#f-851",
"net_income_attributable_to_intuitive_surgical": "d2#f-173",
"basic_eps": "d2#f-177",
"diluted_eps": "d2#f-181",
"basic_shares": "d2#f-185",
"diluted_shares": "d2#f-189"
},
"revenue_by_type": {
"instruments_and_accessories": "d2#f-589",
"systems": "d2#f-593",
"services": "d2#f-597",
"total_revenue": "d2#f-601"
},
"revenue_by_geography": {
"united_states": "d2#f-569",
"outside_united_states": "d2#f-585"
},
"shareholder_returns": {
"shares_repurchased": "d2#f-838",
"aggregate_cost_of_shares_repurchased": "d2#f-842"
},
"balance_sheet": {
"total_intuitive_surgical_stockholders_equity": "d2#f-857",
"noncontrolling_interest_in_joint_venture": "d2#f-858",
"total_stockholders_equity": "d2#f-859",
"common_shares_outstanding": "d2#f-852",
"additional_paid_in_capital": "d2#f-854",
"retained_earnings": "d2#f-855",
"accumulated_other_comprehensive_income_loss": "d2#f-856"
}
}
]
}
}